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Purpose: Recent literature suggests a genetic component for non-arteritic anterior ischemic optic neuropathy (NAION).
We examined the association of the insertion/deletion (I/D) polymorphism of the angiotensin-converting enzyme gene,
of the M235T polymorphism of the angiotensinogen gene, and of the A1166C polymorphism of the angiotensin II type
1 receptor gene with NAION.
Methods: Forty-seven patients with NAION and 76 controls, age- and gender-matched, were recruited and genotyped
for renin-angiotensin-aldosterone system (RAAS) genes. Genotypes were determined by polymerase chain reaction and
restriction enzyme analysis. NAION and control groups were compared in regard to the prevalence of renin-angiotensin-
aldosterone system polymorphisms, and further stratified by age and gender.
Results: NAION occurrence was not associated with the M235T polymorphism of the angiotensinogen gene and the
A1166C polymorphism of the angiotensin II, type 1 receptor gene. Regarding the angiotensin-converting enzyme
insertion/deletion polymorphism, our findings suggest that the II genotype could be a risk factor for NAION in younger
male patients when compared to all cases and controls (p=0.033, odds ratio=5.71, confidence interval=1.152¨C28.35 and
p=0.03, odds ratio=5.33, confidence interval=1.17¨C24.31 respectively). Furthermore I allele was present in all male
patients younger than 55 years, making this allele a likely predisposing factor for NAION in young males.
Conclusions: Since NAION may occur when compromised watershed microcirculation is combined with insufficient
autoregulation of systematic circulation, polymorphisms of genes involved in systematic circulation, such as the RAAS
genes, may be associated with NAION occurrence. Large-scale, multicentered, controlled prospective studies are needed
to further explore the effects of RAAS polymorphisms or other genetic factors on NAION susceptibility.
Anterior ischemic optic neuropathy (AION), is a vision
loss-threatening disease caused by an infarction of the optic
nerve, primarily affecting patients older than 55 years [1].
Over  a  few  days,  optic  disc  edema  develops,  sometimes
associated with flame hemorrhages of the swollen disc or
nearby  cotton-wool  exudates.  Visual  loss  is  usually
permanent, with minor recovery within the first weeks or
months. Optic disc edema is followed within the next few
weeks by optic atrophy of varying degrees that is generalized
or sectorial [2].
Anterior ischemic optic neuropathy (AION) occurs in
two forms: arteritic and nonarteritic (NAION). The arteritic
type is associated with giant-cell arteritis, whereas in NAION
cases, hypertension, diabetes mellitus, ischemic heart disease,
dyslipidemia,  hypercoagulable  states,  and  sleep  apnea
syndrome have been described as risk factors [2-6]. Reports
of the familiar NAION [7], with its predominance among
whites [8] and its possible association with human leukocyte
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antigen  (HLA)-A-29  [9],  suggest  a  genetic  component  in
NAION development. Therefore, NAION may occur when a
genetic  predisposition  is  combined  with  a  variety  of  risk
factors and anatomic variants, such as crowded optic disc
syndrome [10].
Recent studies have examined, with conflicting results,
the association of NAION with thrombophilic genes such as
the  methylenetetrahydrofolate  reductase  (MTHFR)  C677T
polymorphism  and  platelet  polymorphisms  on  the
glycoprotein Ib alpha gene [2,4,5,11], and with hypertension
genes [12], hereditary deficiencies of protein C, protein S and
antithrombin  III,  hyperhomocysteinemia,  and  primary
antiphospholipid syndrome [5,6,13,14].
The  renin-angiotensin  system  genes  exhibit  three
common  polymorphisms:  the  insertion/deletion  (I/D)
polymorphism of the angiotensin-converting enzyme (ACE)
gene, the M235T polymorphism of the angiotensinogen gene
(AGT), and the A1166C polymorphism of the angiotensin II
type 1 receptor gene (AT1-receptor). There is sound evidence
to indicate that variations of renin-angiotensin-aldosterone
system  (RAAS)  genes  may  confer  an  increased  risk  for
hypertension,  preeclampsia,  cardiovascular  disease,  and
stroke [15-18].
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1254In the present study, we examined the association of these
three RAAS gene polymorphisms with NAION in a reference
center  in  Northwest  Greece,  a  well  defined  area  with  a
homogeneous population and limited recent immigration.
METHODS
Study  participants:  The  NAION  patients  studied  were
recruited from January 2004 to December 2007. A detailed
medical  history  was  obtained  and  thorough  physical
examinations of all patients were performed. For diagnosis of
NAION, all patients met the established criteria, including
sudden visual loss, relative afferent papillary defect, visual-
field defects consistent with ischemic optic neuropathy, and
characteristic  fundus  changes  (swollen,  pale  optic  disc
surrounded  by  splinter-shaped  hemorrhages,  followed  by
optic atrophy).
Exclusion criteria were erythrocyte sedimentation rates
over 33 mm in the first hour for men and over 35 mm in the
first hour for women, and any clinical or paraclinical evidence
of autoimmune or rheumatic disease.
The  epidemiological,  clinical  laboratory  features  and
known risk factors for atherosclerosis (hypertension, diabetes
mellitus, dyslipidemia) were evaluated in all patients with
NAION.  Arterial  hypertension  was  defined  when  clearly
documented (>140/90 mmHg) or treated. Diabetes mellitus
was defined as present, if fasting glucose was greater than
126 mg/dl or was being treated with antidiabetic medication.
Dyslipidemia was defined as fasting when cholesterol was
over 220 mg/dl or when the patient was currently being treated
with hypolipidemic agents.
The control group comprised healthy volunteers with no
stroke or history of stroke, or any etiology of optic neuritis,
and a normal computed-tomography brain scan. A standard
neurologic, ophthalmological, and fundoscopic examination
documented  the  absence  of  stroke  or  neuritis,  and  a
standardized questionnaire assessed the absence of previous
ischemic cardio-cerebro-vascular events. They were matched
to  the  cases  for  age  and  gender,  and  were  evaluated  for
hypertension, diabetes mellitus, and dyslipidemia.
All patients and controls were free from autoimmune
diseases  and  negative  for  lupus  anticoagulant  and  other
coagulopathies.
The study protocol was in accordance to the Helsinki
declaration, approved by the Institutional Protocol and Ethics
Review Committee. All participants gave informed consent.
Genetic analysis: Whole blood samples from both patients
and  controls  were  used  for  isolation  of  peripheral  blood
leukocytes  for  genetic  analysis.  Genomic  DNA  (hereafter
DNA) from each individual was isolated using a standard
NaCl extraction procedure. Briefly, in a 1.5 ml tube with
700 μl of peripheral blood, 700 μl of lysis buffer (10 mM Tris-
HCl pH 7.8, 2 mM EDTA (Invitrogen, Carlsbad, CA) 10 mM
KCl, 4 mM MgCl2 [Merk Chemical, Darmstadt, Germany])
and 2 drops of IGEPAL CA-630 (Sigma-Aldrich Company
LTD, UK) were added, were gently vortexed and centrifuged
at 6500× g for 1 min. The supernatant was removed and the
pellet resuspended in 500 μl of lysis buffer and centrifuged at
6500× g for 1 s (wash step). The wash step was repeated for
3–5 times. After the washes the pellet was resuspended in
200 μl of lysis buffer and 15 μl 15% SDS (Sigma-Aldrich
Company LTD) and was placed in waterbath at 55 °C for 5
min.
Following incubation 85 μl of NaCl 6M (Merk Chemical)
were  added  and  centrifuged  at  9600×  g  for  3  min.  The
supernatant  was  resuspended  at  750  μl  of  ice-cold  100%
ethanol (Sigma-Aldrich Company LTD) to precipitate the
DNA. The precipitated DNA was transferred to another 1.5 ml
tube with 50 μl of TE (10 mM Tris-HCl pH 7.8, 1 mM EDTA
pH 8.0-Invitrogen).
The I/D polymorphism in intron 16 of the ACE gene was
analyzed  according  to  Rigat  [19].  To  determine  the  ACE
insertion/deletion  genotype,  PCR  amplification  was
performed in a total volume of 25 μl consisting of 150 ng
extracted  DNA,  0.2  mM  Deoxynucleotide  Triphosphates
(dNTPs; Invitrogen), 10 pmol of each primer (Invitrogen),
10× Taq DNA polymerase buffer (Invitrogen), 2 mM MgCl2
(Invitrogen),  5%  dimethyl  sulfoxide  DMSO  (Euroclone,
Milano,  Italy),  and  1.25  units  of  Taq  DNA  polymerase
(Invitrogen).  The  forward  and  reverse  primers  were,
respectively:  5′-CTG  GAG  ACC  ACT  CCC  ATC  CTT
CTC-3′ and 5′-GAT GTG GCC ATC ACA TTC GTC AGA
T-3′. The thermal cycling was as follows: 10 min denaturation
at 94 °C, 30 cycles of 94 °C for 45 s, 58 °C for 30 s, and 72 °C
for 45 s, with a final extension at 72 °C for 10 min. The final
products, one of 490 bp with the insert (I allele) and one of
190 bp without the insert (D allele), were separated on 2%
agarose gel. The resulting genotypes were DD, ID, and II.
For  AGT  M235T  allele  determination,  PCR  was
performed  according  to  a  previously  described  procedure
[20]. Briefly, the AGT M235T genotype was determined by
PCR amplification in a 25 μl mixture of 150 ng of extracted
DNA, 0.2 mM dNTPs (Invitrogen), 5 pmol of each primer
(forward: 5′-CAG GGT GCT GTC CAC ACT GGA CCC
C-3′; reverse: 5′-CCG TTT GTG CAG GGC CTG GCT CTC
T-3′), 10x Taq DNA polymerase buffer (Invitrogen), 1.5 mM
MgCl2 (Invitrogen), 5% DMSO (Euroclone), and 1 unit of Taq
DNA polymerase (Invitrogen). The thermocycling conditions
were as follows: at 90 °C for 3 min, 10 cycles at 94 °C for 1
min, at 68 °C for 1 min, and at 72 °C for 1 min, then continued
with 30 cycles at 90 °C for 30 s, at 68 °C for 1 min, and at
72 °C for 30 s, with a final extension at 72 °C for 10 min. The
PCR  products  were  digested  at  37  °C  for  6  h  with  the
restriction  enzyme  Tth111I  (New  England  Biolabs-NEB,
Hitchin,  UK).  Digestion  products  were  separated  by  2%
agarose gel electrophoresis and visualized by exposure to
ultraviolet light after ethidiun bromide (Invitrogen) staining.
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1255The  lengths  of  the  separated  fragments  were  165  bp,
corresponding  to  the  M235  allele  (M),  and  141  bp,
corresponding to the digested T235 allele (T). The resulting
genotypes were MM, MT, and TT.
To  determine  AT1-receptor  A1166C  genotypes,  PCR
amplification was also performed using standard procedures
[21]. PCR amplification was performed in a total volume of
25 μl consisting of 150 ng extracted DNA, 0.2 mM dNTPs
(Invitrogen), 4 pmol of each primer (Invitrogen), 10x Taq
DNA  polymerase  buffer  (Invitrogen),  2  mM  MgCl2
(Invitrogen),  and  one  unit  of  Taq  DNA  polymerase
(Invitrogen). The forward and reverse primers were: 5′-GCA
CCA TGT TTT GAG GTT-3′ and 5′-CGA CTA CTG CTT
AGC ATA-3′, respectively. The reaction was performed using
the  following  protocol:  denaturation  for  5  min  at  94  °C,
followed by 40 cycles of denaturation (94 °C, 30 s), annealing
(52 °C, 30 s), and extension (72 °C, 30 s), and a final 10 min
extension at 72 °C. The amplified product was digested for 3
h  at  37  °C  with  the  Dde1  (New  England  Biolabs-NEB)
restriction enzyme, electrophoresed in 2% agarose gel, and
visualized by staining with ethidium bromide (Invitrogen).
Amplification  of  the  A  allele  resulted  in  a  546  bp  DNA
fragment.
Digestion  of  the  C  allele  resulted  in  a  435  bp  DNA
fragment. The resulting genotypes were AA, AC, and CC. All
samples were run in duplicates with positive and negative for
each genotype sample as controls and blanks.
Statistical  analysis:  The  gene  counting  method  estimated
allele frequencies at the individual loci. The agreement of
genotype  frequencies  with  Hardy–Weinberg  equilibrium
expectations was tested using the χ2 test. Statistical analysis
was performed using the statXact program. All p values were
two-tailed  and  were  considered  statistically  significant  at
p<0.05. Confidence intervals (CIs) were calculated at the 95%
level. Odds ratios (ORs) were defined as the odds ratio of
patients  with  NAION  divided  by  the  odds  of  the  control
groups, and were calculated to provide an estimate of the
relative risk of RAAS polymorphisms associated with NAION.
RESULTS
Forty-seven patients (29 men and 18 women) and 76 controls
(47 men and 29 women) were recruited for the study. The
patients’ ages ranged from 49 to 85 years, with a mean age of
66.2 years. The age range of the controls was from 48 to 75
years, with a mean age of 65.6 years. Most cases were older
than 55 years, and only eight patients were younger (six men
and two women). In the control group, 11 individuals (eight
men  and  three  women)  were  under  55  years  of  age.
Epidemiological and other relevant clinical data are shown in
Table 1.
The  polymorphisms  were  in  Hardy–Weinberg
equilibrium in the study population and the control group. The
genotype and allele distributions are shown in Table 2. No
statistically significant difference, regarding genotypes and
alleles, was found for the three polymorphisms between the
control and patient groups.
Despite these negative results, when correlations were
made according to age and gender (Table 3), some noteworthy
findings emerged for the I/D polymorphism.
Regarding age, the II genotype frequency was higher in
the younger age group ≤50 years (50%), compared to the cases
(14.9%), the whole controls (15.8%), and the subgroup of
controls ≤55 years (18.1%). This difference was statistically
significant when patients at or below 55 years were compared
to all cases and the controls, while there was no significant
difference in comparison to the controls at or below 55 years
(p=0.033, OR=5.71, CI=1.152–28.35; p=0.03, OR=5.33, CI:
1.170–24.31 and p=0.15, respectively).
Regarding gender, no significant difference was found
when  male  cases  were  compared  to  male  controls.  When
comparisons  were  made  according  to  age  and  gender
simultaneously,  there  was  a  significant  difference  in  the
frequency of the II genotype in male cases at or below 55 years
(66.6%) in comparison to all male cases and the male controls
(p=0.023, OR=9.6, CI: 1.363–67.60 and p=0.007, OR=13.67,
CI: 2.04–91.49, respectively).
Allele I of the ACE gene was more frequently present in
patients, compared to controls (72.3% in cases versus 60.5%
in controls), especially in younger patients under 55 years of
age (87.5% in patients at ≤55 years versus 72.7% in controls
at ≤55 years), but without statistical significance. Following
an age-gender approach, comparison of male patients under
TABLE 1. CLINICAL CHARACTERISTICS OF PATIENTS AND CONTROLS
Data Cases (n=47) Controls (n=76)
Males 29 (61.7) 47 (61.8)
Females 18 (38.3) 29 (38.1)
Age, mean 66.2 65.6
Hypertension 28 (59.5) 42 (55.2)
Diabetes mellitus 12 (25.5) 19 (25)
Dyslipidemia 20 (42.5) 31 (40.7)
                  Numbers in parentheses for nominal data indicate percentages and for continuous ±SD
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125655 years to all male cases showed that the I allele was present
in all six younger male patients (100%).
Regarding the M235T polymorphism of the AGT gene
and the A1166C the polymorphism of the AT1-receptor gene,
any correlation between gender and age groups disclosed no
statistically  significant  difference  in  allele  and  genotype
distributions.  As  a  result,  no  association  of  these  two
polymorphisms with NAION occurrence was identified.
DISCUSSION
A finding that surfaced from our study concerned the ACE I/
D polymorphism, suggesting that the II genotype is a risk
factor for NAION in younger patients, especially men, and
that the I allele is likely a predisposing factor for NAION in
younger males, but not in younger females (≤55 years). We
did  not  find  any  association  between  the  M235T  AGT
polymorphism,  the  A1166C  AT1-receptor  polymorphism,
and NAION occurrence
Although apoplectic onset, disc swelling, hyperemia, and
splinter hemorrhages support infarction as the precipitating
event  in  NAION,  the  precise  mechanism  of  optic  nerve
ischemia  has  not  been  absolutely  clarified,  and  the
contribution of the various known vascular risk factors is not
entirely known. The optic nerve disc has a unique vasculature
with contributions from the short posterior ciliary arteries, the
pial  circulation,  and  the  retinal  circulation  [22],  with  an
autoregulatory  mechanism  controlling  blood  flow.  This
arrangement produces watershed zones at the boundaries of
supply from adjacent circulations. When this mechanism is
deficient, ischemia may occur. It has been suggested that
NAION  may  be  the  result  of  a  compromised  watershed
microcirculation,  via  mechanisms  different  from
cerebrovascular  and  cardiovascular  events.  NAION  is  not
clearly a thrombotic or an embolic disease, as has been shown
by studies demonstrating no increased risk of cerebrovascular
disease in NAION patients [3,23].
Recent literature indicates that NAION is associated with
nocturnal  arterial  hypotension,  which  may  produce
hypoperfusion of the optic nerve head microvasculature [24].
NAION  development  within  hours  of  using
phosphodiesterase type-5 inhibitors has also been described
[25], with the blunting of vasculoprotective actions of nitric
oxide  through  cyclic-GMP  hydrolysis  by  the
phosphodiesterase  type-5  inhibitor  being  a  possible
mechanism [26]. Therefore, altered vascular regulation, due
to nitric oxideconcentration changes, may result in NAION in
particular  patients.  Consequently,  insufficient  or  altered
autoregulatory circulation mechanisms may provoke NAION
development. Polymorphisms of genes involved in systematic
circulation, such as the RAAS and vasculoprotective genes,
may, like the NOS genes, have a role in NAION occurrence,
although results conflict [27,28].
The  rennin-angiotensin-aldosterone  system  plays  a
central role in blood pressure regulation, and RAAS genes have
been shown to affect blood pressure phenotypes [29,30]. The
ACE I/D polymorphism appears to influence ACE expression
and blood pressure, with the D allele and DD genotype being
associated with high blood pressure, while the II genotype and
the I allele are associated with lower blood pressure [31,32].
The T allele of the M235T polymorphism of AGT is also
associated with increased blood pressure [33,34], whereas
contradictory evidence exists for the A1166C polymorphism
of  the  AT1-receptor  gene  [35,36].  Furthermore,  previous
studies have demonstrated that the RAAS genotypes have a
gender  dimorphism  concerning  their  influence  on  ACE
plasma concentration [37], the molar ratio of Ang II to Ang-
(1–7) [38], and the renin and pro-renin concentrations [39],
suggesting that gene regulation of RAAS is affected by the
TABLE 2. GENOTYPE AND ALLELE DISTRIBUTIONS OF RAS POLYMORPHISMS IN PATIENTS AND CONTROLS
Genotypes/alleles Patients (47) Controls (76)
ID 26 (55.3%) 34 (44.7%)
DD 14 (29.8%) 30 (39.5%)
II 7 (14.9%) 12 (15.8%)
AC 20 (42.6%) 31 (40.8%)
AA 25 (53.2%) 40 (52.6%)
CC 2 (4.2%) 5 (6.6%)
MT 23 (48.9%) 40 (52.6%)
MM 17 (36.2%) 24 (31.6%)
TT 7 (14.9%) 12 (15.8%)
D allele presence 40 (85.1%) 64 (84.2%)
I allele presence 33 (70.2%) 46 (60.5%)
A allele presence 45 (95.7%) 71 (93.4%)
C allele presence 22 (46.8%) 36 (47.3%)
M allele presence 40 (85.1%) 64 (84.2%)
T allele presence 30 (63.8%) 52 (68.4%)
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1257gonadal steroids [40,41]. As a result, in many studies, the DD
genotype  is  associated  with  an  increased  risk  of  cardiac
hypertrophy and hypertension among men, without a similar
association being present among women [41,42].
Our  results  do  not  indicate  that  certain  RAAS
polymorphisms play a role in NAION onset. The suspected
influence on the I allele and II genotype in ages below 55 years
is  intriguing  and  may  support  the  hypothesis  that
hypoperfusion  and  low  pressure  are  possible  underlying
causes  of  NAION  in  this  age  group  [30].  A  possible
unfavorable effect of the II genotype in males is also present,
in accordance with the aforementioned sexual dimorphism of
the RAAS genes [41,42].
The small number of patients younger than 55 years made
the comparisons less conclusive, and the small number of
younger women did not permit any comparisons between
younger  and  older  women  or  between  younger  men  and
women. The strength of our study is its use of an homogenous
population affected only with limited immigration the last
century.
In summary, our study, despite some negative results and
other limitations, uncovered interesting findings on blood-
pressure gene polymorphisms and NAION susceptibility. It
is, to our knowledge, the first study to attempt gender- and
age-related  analysis  of  these  patients.  Large-scale,
multicentered, controlled prospective studies are needed to
further explore the effects of RAAS polymorphisms and other
genetic factors on NAION susceptibility.
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